Details

Autor(en) / Beteiligte

• Shibayama, Hirohiko
• Itagaki, Mitsuhiro
• Handa, Hiroshi
• Yokoyama, Akihiro
• Saito, Akio
• Kosugi, Satoru
• Ota, Shuichi
• Yoshimitsu, Makoto
• Tanaka, Yasuhiro
• Kurahashi, Shingo
• Fuchida, Shin-ichi
• Iino, Masaki
• Shimizu, Takayuki
• Moriuchi, Yukiyoshi
• Toyama, Kohtaro
• Mitani, Kinuko
• Tsukune, Yutaka
• Kada, Akiko
• Tamura, Hideto
• Abe, Masahiro
• Iwasaki, Hiromi
• Kuroda, Junya
• Takamatsu, Hiroyuki
• Sunami, Kazutaka
• Kizaki, Masahiro
• Ishida, Tadao
• Saito, Toshiki
• Matsumura, Itaru
• Akashi, Koichi
• Iida, Shinsuke

Titel

Primary analysis of a prospective cohort study of Japanese patients with plasma cell neoplasms in the novel drug era (2016–2021)

Ist Teil von

• International journal of hematology, 2024-06, Vol.119 (6), p.707-721

Ort / Verlag

Singapore: Springer Nature Singapore

Erscheinungsjahr

2024

Link zum Volltext

Quelle

SpringerLink

Beschreibungen/Notizen

• The emergence of novel drugs has significantly improved outcomes of patients with plasma cell neoplasms (PCN). The Japanese Society of Hematology conducted a prospective observational study in newly diagnosed PCN patients between 2016 and 2021. The analysis focused on 1385 patients diagnosed with symptomatic PCN between 2016 and 2018. The primary endpoint was the 3-year overall survival (OS) rate among patients requiring treatment ( n  = 1284), which was 70.0% (95%CI 67.4–72.6%). Approximately 94% of these patients received novel drugs as frontline therapy. The 3-year OS rate was 90.3% (95%CI 86.6–93.1%) in the 25% of patients who received upfront autologous stem cell transplantation (ASCT), versus just 61.4% (95%CI 58.0–64.6%) in those who did not receive upfront ASCT. The only unfavorable prognostic factor that affected OS in ASCT recipients was an age of 65 or higher. For patients who did not receive ASCT, independent unfavorable prognostic factors included frontline treatment with conventional chemotherapies, international staging system score of 2/3, extramedullary tumors, and Freiberg comorbidity index of 2/3. This study unequivocally demonstrates that use of novel drugs improved OS in Japanese myeloma patients, and underscores the continued importance of upfront ASCT as the standard of care in the era of novel drugs.